[1] Otteneder M,Lutz WK. Correlation of DNA adduct levels with tumor incidence:carcinogenic potency of DNA adducts[J].Mutation Research,1999.237-247.
[2] Ross RK,Yuan JM,Yu MC. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma[J].Lancet,1992.943-946.
[3] Tang DL,Rundle A,Warburton D. Associations between both genetic and environmental biomarkers and lung cancer:evidence of a greater risk of lung cancer in women smokers[J].Carcinogenesis,1998.1949-1953.
[4] Stacey LT,Stephen PE,Kevin KC. Benzo[a] pyrene and TCDD-induced alteration in tyrosine phosphorylation and insulin-like growth factor signaling pathways in the MCF-10A human mammary epithelial cell line[J].Carcinogenesis,1998.1291-1297.
[5] Wendy AS,Ramesh CG. Determining efficacy of cancer chemopreventive agents using a cell-free system concomitant with DNA adductions[J].Mutation Research,1999.143-152.
[6] Turteltaub KW,Felton JS,Gledhill BL. Accelerator mass spectrometry in biomedical dosimetry:Relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA[J].Proceedings of the National Academy of Sciences of the United States of America,1990.5288-5292.
[7] Felton JS,Turteltaub KW,Vogel JS. Accelerator mass spectrometry in biomedical science s:Applications in low exposure biomedical and environmental dosimetry[J].Nuclear Instruments and Methods in Physics Research,1990.517-523.
[8] Turteltaub KW,Felton JS,Gledhill BL. Accelerator mass spectrometry in biomedical dosimetry:Relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA[J].Proceedings of the National Academy of Sciences of the United States of America,1990.5288-5292.
[9] Vogel JS. Rapid production of graphite without contamination for biomedical AMS[J].Radiocarbon,1992.344-350.